Abstract
PurposeTo investigate the clinical efficacy and safety of wearable antioxidant glasses containing extracts of medicinal plants in patients with mild dry eye disease (DED).MethodsFifty patients with mild DED were randomly assigned to wear either extracts of antioxidant medicinal plants containing (N = 25) or placebo glasses (N = 25). Patients wore the glasses for 15 min three times daily. The ocular surface disease index (OSDI) score, tear film break up time (BUT), and Schirmer’s test were evaluated and compared within the group and between the groups at baseline, 4 weeks, and 8 weeks after treatment.ResultsOSDI score and tear film BUT were significantly improved in the treatment group at 4 and 8 weeks after wearing glasses (all P < 0.001). Compared to the placebo group, the OSDI scores were significantly lower in the treatment group at 8 weeks (P = 0.007). The results of the Schirmer’s test showed significant improvement in the treatment group at 4 weeks (P = 0.035), however there were no significant differences between the other groups or within the groups. No adverse events were reported during the study.ConclusionsAntioxidant glasses containing extracts of medicinal plants were effective in improving in DED both subjectively and objectively. Wearing antioxidants glasses might be a safe and adjunctive therapeutic option for DED.Trial RegistrationISRCTN registry 71217488
Highlights
Dry eye disease (DED) is one of the most common ocular surface disorder that significantly affects quality of human life
Compared to the placebo group, the ocular surface disease index (OSDI) scores were significantly lower in the treatment group at 8 weeks (P = 0.007)
Antioxidant glasses containing extracts of medicinal plants were effective in improving in DED both subjectively and objectively
Summary
Dry eye disease (DED) is one of the most common ocular surface disorder that significantly affects quality of human life. Epidemiologic studies have reported that more than 15% of people suffer from DED worldwide. DED has become one of the leading reasons for patients to seek ophthalmological care.[1] the pathogenesis of DED has not been established clearly, it is well known that immune-mediated inflammation on the ocular surface plays a prominent role.[2] Current treatments for DED include life style modification, topical lubrication with artificial tears, topical anti-inflammatory and immunemodulatory agents, or punctal occlusion.[3] such therapeutic methods are often unsatisfactory or not well tolerated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
